GLP-1 medications & the Bridge program
A side-by-side look at the GLP-1 drugs most relevant to Medicare coverage — what they treat, how they're taken, and typical results.
"GLP-1" medications mimic a gut hormone that regulates appetite and blood sugar. Several are FDA-approved, but they differ in their approved indications — which matters because Bridge/Part D coverage is tied to a qualifying use. Below, compare the most common options. Whether a specific drug is on your plan's formulary varies, so always check your plan's drug list.
Quick comparison
| Drug | Maker | Active ingredient | Primary FDA use | How taken | Avg. weight loss* |
|---|---|---|---|---|---|
| Wegovy | Novo Nordisk | Semaglutide 2.4mg | Chronic weight management; CV risk reduction | Weekly injection | ~15% at 68 wks |
| Zepbound | Eli Lilly | Tirzepatide | Chronic weight management; OSA | Weekly injection | ~20% at 72 wks |
| Ozempic | Novo Nordisk | Semaglutide 1–2mg | Type 2 diabetes | Weekly injection | ~6–13% |
*Average total body-weight change reported in pivotal clinical trials; individual results vary. See an estimated curve on our weight-loss projection tool. Sources: FDA.gov labeling.
Which drug does the Bridge program cover?
Coverage follows your plan's formulary and your qualifying condition. A drug approved for your specific indication (e.g., Wegovy for cardiovascular risk, Ozempic for type 2 diabetes) is more likely to be covered than off-label use.
Check your eligibility →See your projected results
Curious how much weight you might lose over time on Wegovy or Zepbound? Our projection tool maps a week-by-week estimate based on clinical-trial averages.
Open weight projection tool →Important safety note
GLP-1 medications carry possible side effects and contraindications. This page is educational and does not recommend any specific drug. Your prescriber will weigh your full medical history.